Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
World Stroke Congress | TASTE-2 significantly reduces stroke disability 2024-10-30 15:36
TASTE-2 World Stroke Congress | Sanbexin ® combined with thrombectomy significantly reduces stroke disability 2024-10-25 15:14
Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration 2024-09-14 19:43
Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration 2024-09-05 13:49
Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor 2024-09-02 20:24
Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA 2024-06-26 12:36
Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart 2023-11-23 16:04
Four innovative drugs launched in three years, HKEX -Listed Simcere Pharmaceutical Group is on the Fast Track Toward Building an Innovation-Driven Global Pharmaceutical Company 2023-04-24 18:09
Simcere Zaiming Announces Clinical Collaboration to Evaluate SIM0235, a TNFR2 Monoclonal Antibody, in Combination with KEYTRUDA® (pembrolizumab) in a Phase 1 Trial in Advanced Solid Tumors and Cutaneous T-cell Lymphoma 2023-03-14 20:00
First Prescription for COSELA® (trilaciclib) Issued in China 2023-02-09 21:00
PHASE II/III CLINICAL TRIAL OF SIMCERE'S 3CL-TARGETING ANTI-SARS-COV-2 DRUG CANDIDATE COMPLETE ALL PATIENTS ENROLLMENT 2022-12-20 19:21
Simcere and Idorsia enter into a licensing agreement for daridorexant in China 2022-11-16 08:32
Simcere Receives FDA Clearance of Investigational New Drug Application (IND) for Bi-functional Fusion Protein, SIM0237 2022-10-27 21:25
Simcere and Almirall Enter into a Licensing Agreement for IL-2 mu-Fc 2022-09-29 11:32
Simcere Pharmaceutical Announces Financial Results for 2022 H1: 27% Year-Over-Year Revenue Growth, with Innovative Drugs Accounting for 65.4% of Total Revenue 2022-09-05 13:09
Tamas Oravecz Ph.D. named SVP, CSO of the U.S. of Simcere Pharmaceutical Group 2022-09-05 13:08
SIMCERE PHARMA (HK.2096) Novel Inhibitor of COVID-19 3CLpro SIM0417 Received a Second Clinical Trial Approval in China 2022-05-18 11:56
Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in Clinical Trials, Market Approval of Trilaciclib Expected in China, Simcere Reveals Global Innovation Ambition on R&D Day 2022-04-19 10:28
SIMCERE PHARMA (HK.2096) to host 2022 R&D Day 2022-04-07 21:39
Primary endpoint met in Phase III clinical trial of Trilaciclib in Chinese patients with small cell lung cancer 2022-02-24 13:34
1 2